MOTS-c with SS-31
MOTS-c with SS-31 (elamipretide) mitochondrial blend
Written by Aaron CuhaReviewed Sep 2026
Also known as: Mitochondrial stack, MOTS-c elamipretide blend
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Two mitochondria peptides sold as one stack, mostly to people who are tired all the time. SS-31 is a real drug that went through proper testing. MOTS-c has never been given to a person in a published study.
What people take it for
- Energy and stamina.
- Long term fatigue that nothing has fixed.
- Better workouts.
- Blood sugar control.
What the trials actually showed
Nobody has tested the pair. SS-31 went into a phase 3 trial in adults with a mitochondrial muscle disease. It did not work. The trial did not show a real benefit in the group it studied. Then they went back and looked at smaller groups inside it. People with one specific type of gene fault walked 25.2 metres further in six minutes. The dummy group got 2.0 metres. That just missed the line for being a real result. A smaller group with a particular eye muscle problem walked 37.3 metres further while the dummy group got 8.0 metres worse, and that one did cross the line. Those groups are people with a diagnosed genetic disease, not people who are tired. The authors say the point of that digging was to design the next trial. MOTS-c has no human trial at all. Its work is in fat mice. The senior author on that paper discloses he consults for and owns stock in a mitochondrial peptide company.
What people report
Reports, not trial results
The good
- More energy or stamina within a few weeks.
- Better exercise tolerance in people with long standing fatigue.
The bad
- Nothing at all, reported often.
- Sore shot sites.
- Neither has a legal source, and nobody has tested what is actually in seller vials.
- Fatigue moves around a lot by itself, so it is very hard to know what did what.
Where these come from: Peptide forums, fatigue communities and clinic write-ups. People talking, about a symptom that comes and goes on its own.
My bottom line
A failed trial with a promising subgroup is not a drug that works. It is a reason to run another trial. And the other half has never been in a person at all.
An opinion, not a finding. I am a coach, not a doctor.
Overview
Two mitochondrial peptides sold as one stack. SS-31 is elamipretide, which reached phase 3 in primary mitochondrial myopathy and did not demonstrate a significant benefit in its overall trial population. MOTS-c has no human trial at all. The combination has never been studied and vendors do not agree on vial sizes.
This pairing is sold to people with fatigue, and the two halves have very different evidentiary situations that get flattened into one product page.
SS-31 is elamipretide, a real investigational drug that went through a proper development programme. MMPOWER-3 was a phase 3 trial in adults with primary mitochondrial myopathy, and as published it did not demonstrate a significant benefit of elamipretide in that genotypically diverse population. A prespecified subgroup with nuclear DNA pathogenic variants did improve on the six-minute walk test, and post hoc analysis found the mitochondrial DNA replisome cohort improved by 25.2 metres against 2.0 metres on placebo at p = 0.06, with a significant 37.3 metre improvement against a 8.0 metre decline in the subset with chronic progressive external ophthalmoplegia at p = 0.0024. Those subgroup findings are the basis for a follow-up phase 3 trial rather than a result in themselves.
That is an unusually honest evidence picture and it is worth reading carefully. The main trial was negative. The subgroups that responded are defined by specific genetic diagnoses that almost nobody buying a peptide vial has, and the post hoc nature of most of that analysis is stated by the authors.
MOTS-c is a mitochondrially encoded peptide with no human trial. Its literature is mouse work: an unbiased metabolomics study found MOTS-c injection reduced sphingolipid, monoacylglycerol and dicarboxylate metabolism pathways in diet-induced obese mice, pathways that are upregulated in obesity and type 2 diabetes models, and describes MOTS-c as improving insulin sensitivity and reducing body weight and fatty liver in those mice. The senior author on that work is a consultant and stockholder in a company developing mitochondrial peptides, disclosed in the paper.
Vial sizes vary across sellers and no split is canonical, so this page does not state a per-unit figure. The structural point holds regardless: elamipretide in its trials was dosed as a single agent on a defined schedule under supervision in people with a diagnosed mitochondrial disease, and a blended vial bought online is none of those things.
Mechanism of action
SS-31 is an aromatic cationic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane and is described as stabilising membrane structure and improving electron transport efficiency. MOTS-c is encoded in mitochondrial DNA and is described as activating AMPK and regulating metabolic pathways. The two mechanisms are genuinely different, which is the better version of the blend rationale, and nobody has tested whether they add.
Human evidence
One component failed its phase 3 primary analysis and showed subgroup signals in rare genetic diagnoses. The other has no human data. The blend has none.
- The blend: no published study, no registered trial.
- Elamipretide, MMPOWER-3: did not demonstrate a significant benefit in the overall primary mitochondrial myopathy population.
- Elamipretide subgroups: 25.2 metres against 2.0 metres on the six-minute walk in the replisome cohort at p = 0.06, and 37.3 metres against a 8.0 metre decline in the chronic progressive external ophthalmoplegia subset at p = 0.0024, mostly post hoc.
- MOTS-c: no human trial of any kind. The evidence is diet-induced obese mice.
What this does not tell you: The elamipretide subgroup findings apply to people with specific diagnosed genetic mitochondrial disorders, which is not the population buying a fatigue stack. Post hoc subgroup results are hypothesis-generating by construction, and the authors say so.
What it has been measured to do
Measured in people
Goals MOTS-c with SS-31 has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Getting strongerno headcount stated · 1 study
Measured in animals or cells, not yet in people
Real results that answer a different question from a trial. Where a human trial is missing on a compound nobody can patent, the reason is usually that no sponsor would ever recover the cost of running one. The record on this one is set out below.
- Blood sugar and insulin1 preclinical study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with MOTS-c with SS-31, what they expect, and what goes wrong. The full account, including the negative reports, is below.
33 of the 36 indexed goals have no study of any kind behind MOTS-c with SS-31
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about MOTS-c with SS-31 and one of these did not come from a study cited here.
Reading the research record
This blend is a good test of how a reader handles a negative trial with positive subgroups. The correct reading is that elamipretide did not work in the population it was tested in, that a genetically defined subgroup may respond, and that a further trial was designed to find out. That is not the same as a drug that works, and it is certainly not evidence for a person with unexplained fatigue and no mitochondrial diagnosis.
MOTS-c is at an earlier stage than the marketing suggests. It is an interesting molecule with a mouse literature and a disclosed commercial interest behind part of that literature. No human has been given it in a published trial.
One genuine credit to this pairing: unlike most blends in this batch, the two components really do act by different mechanisms. That is a better starting point than two agents at one receptor. It is still a starting point rather than a finding.
The evidence, charted
Fig. 1a · evidence scale
1human study cited, participant count not stated
participants not stated
No participant total is drawn, because none of the human citations on this page gives one. Read the citations below for what each study measured.
Participant counts are read from the citation lines on this page. Where a line states no number, nothing is counted for it rather than estimated.
Fig. 1b · evidence mix
1 of 3 citations here is human work, the rest are not.
- Human · given to people133%
- Animal · given to animals133%
- Review · summarises other work133%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2019 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend. No pharmacokinetic study of the combination exists and neither component has an established dosing interval outside a trial protocol.
No amino acid sequence is on file for MOTS-c with SS-31, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
No mass split can be drawn for this blend
Sellers do not publish a consistent vial size for MOTS-c with SS-31, so the share of each component is not knowable from the outside. Splitting the bar evenly would invent the number this page exists to question.
- MOTS-camount not stated
- SS-31 (elamipretide)amount not stated
Component list from the product labels we hold. Amounts are label mass, never a dose.
Key studies & citations
- Human2024
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial
As previously published, MMPOWER-3 did not demonstrate a significant benefit of elamipretide in a genotypically diverse adult population with primary mitochondrial myopathy. In post hoc analysis the mitochondrial DNA replisome cohort improved 25.2 plus or minus 8.7 metres on the six-minute walk test against 2.0 plus or minus 8.6 metres on placebo at p = 0.06, and the subset with chronic progressive external ophthalmoplegia improved 37.3 plus or minus 9.5 metres against a 8.0 metre decline at p = 0.0024. These analyses were designed to inform a follow-up phase 3 trial.
Orphanet Journal of Rare Diseases - Animal2019
The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity
In diet-induced obese mice, MOTS-c injection reduced three plasma metabolite pathways that are upregulated in obesity and type 2 diabetes models: sphingolipid, monoacylglycerol and dicarboxylate metabolism. The paper describes MOTS-c as improving insulin sensitivity and increasing beta oxidation to prevent fat accumulation in these mice. Mice only. The senior author discloses being a consultant and stockholder in a company developing mitochondrial peptides.
Physiological Reports - Review2026
NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence
A systematic review of the mitochondrial and NAD supplementation field across preclinical and clinical evidence, useful here as the broader context for how often mechanistic mitochondrial findings in animals have translated into measured human outcomes.
Ageing Research Reviews
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- More energy or stamina within a few weeks, the main reason people buy it.
- Better exercise tolerance, particularly in people with long-standing fatigue.
- Nothing at all, reported frequently.
- Injection site reactions.
- Uncertainty about product identity, since neither component has a licensed source and no independent assay of vendor material has been published.
Sources: Peptide forums including r/peptides, chronic fatigue communities and clinic write-ups. Uncontrolled self-reports in a symptom domain that fluctuates substantially on its own.
Frequently asked questions
Did the SS-31 trial work?
The phase 3 trial in primary mitochondrial myopathy did not demonstrate a significant benefit in its overall population. A genetically defined subgroup improved on the six-minute walk test, mostly in post hoc analysis, and a follow-up trial was designed around that.
Is there any human data for MOTS-c?
None. Its literature is mouse work, including a metabolomics study in diet-induced obese mice.
Do the two work by different mechanisms?
Yes, and that is the strongest thing about this pairing. One binds cardiolipin in the inner mitochondrial membrane and one is described as activating AMPK. Whether they add has never been tested.
What is the vial size?
There is no standard. Vendors sell different splits, which is why this page does not print a per-unit figure.
Would this help my fatigue?
The one trial in this pairing's evidence base was in people with diagnosed primary mitochondrial myopathy and did not meet its primary analysis. There is no trial in unexplained fatigue for either component.